Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024 Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries Press release
Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow Press release
